Pharmaceutical policies in European countries in response to the global financial crisis

Southern Med Review

Volumn 4, Issue 2, 2011, Pages 22-32

  Vogler, Sabine ^a   Zimmermann, Nina ^a   Leopold, Christine ^a   de Joncheere, Kees ^b  

^a GESUNDHEIT ÖSTERREICH GMBH   (Austria)

^b WHO Country Office Ukraine   (Ukraine)

Author keywords

Cost containment; Europe; Global financial crisis; Medicines; Policy measures; Pricing; Reimbursement

Indexed keywords

ARTICLE; COST CONTROL; DRUG CONTROL; DRUG COST; DRUG INDUSTRY; DRUG INFORMATION; ECONOMIC RECESSION; EUROPE; HEALTH CARE POLICY; REIMBURSEMENT;

EID: 83055163268     PISSN: 11742704     EISSN: None     Source Type: Journal    
DOI: 10.5655/smr.v4i2.1004     Document Type: Article

References (44)

1. Hogerzeil HV. The concept of essential medicines: lessons for rich countries. BMJ 2004; 329:1169-72.
2. Hogerzeil HV et al. Is access to essential medicines as part of the fulfillment of the right to health enforceable through the courts? Lancet 2006; 368:305-11.
3. Hogerzeil HV. Essential medicines and human rights: what can they learn from each other? Bull World Health Organ. 2006; 84:371-5.
4. World Health Organization. The world medicines situation. Geneva (Switzerland): World Health Organization; 2004.
5. Cameron A et al. Medicine prices, availability, and affordability in 36 developing and middle income countries: a secondary analysis. Lancet 2009; 373:240-9.
6. Gelders S et al. Price, availability and affordability. An international comparison of chronic disease medicines. Cairo: World Health Organization, Regional Office for the Eastern Mediterranean. Health Action International; 2006.
7. WHO. Public-private roles in the pharmaceutical sector: Implications for equitable access and rational drug use. Geneva (Switzerland): World Health Organization; 1997.
8. OECD. Pharmaceutical pricing policies in a global market. Paris: OECD Health Policy Studies; 2008.
9. Vogler S et al. PPRI Report. Vienna: Gesundheit Österreich GmbH/Geschäftsbereich ÖBIG; 2008.
10. Pignatti F et al. Overview of the European regulatory approval system. J Ambul Care Manage. 2004; 27:89-97.
11. Council Directive of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems (89/105/EEC). Available from: http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31989L0105:en:HTML. (7 August, 2011).
12. Vogler S et al. Pharmaceutical Pricing and Reimbursement Information (PPRI) - new PPRI analysis including Spain. Pharmaceuticals Policy and Law 2009; 11:213-34.
13. Espin J, Rovira J. Analysis of differences and commonalities in pricing and reimbursement systems in Europe. Brussels: DG Enterprise and Industry of the European Commission; 2007.
14. Habl C et al. Surveying, assessing and analysing the pharmaceutical sector in the 25 member states. Vienna: ÖBIG; 2005.
15. Vogler S et al. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States, Croat Med J. 2011; 52: 183-97.
16. Mrazek MF. Comparative approaches to pharmaceutical price regulation in the European Union. Croat Med J. 2002; 43:453-61.
17. Mossialos E et al. Regulating pharmaceuticals in Europe: striving for efficiency, equity, and quality. Maidenhead (UK): Open University Press; 2004.
18. Arts D et al. Pharmaceutical Pricing and Reimbursement Information (PPRI): a European Union project. Italian Journal of Public Health 2006;3:36-40.
19. Mantel-Teeuwisse A, Hoebert J. PHIS Evaluation Report. Utrecht: Utrecht University/WHO Collaborating Centre for Pharmacoepidemiology and Pharmaceutical Policy Analysis, 2011
20. PHIS/AIFA/GÖG. PHIS Glossary: Glossary for pharmaceutical policies/systems developed in the Pharmaceutical Health Information System (PHIS) Project. 2009. http://phis.goeg.at/index.aspx?_nav0020. Accessed: March 23, 2011.
21. Vogler S. PPRI policy monitoring query - findings. Presentation at a PPRI Network Meeting. Riga: PPRI; February 2011.
22. Ioannou E. Pharmaceutical Pricing in Greece & Crisis. Presentation at a PPRI Network Meeting. Riga: PPRI; February 2011.
23. Ferré P. Impact of the economic crisis on pharmaceutical pricing and reimbursement of medicines. Experience of Spain. Presentation at a PPRI Network Meeting. Riga: PPRI; February 2011.
24. Mulvenna K. Challenges and opportunities in an economic turndown. Presentation at a PPRI Network Meeting. Riga: PPRI; February 2011.
25. Ognyanova D et al. Pharmaceutical reform 2010 in Germany. Eurohealth 2011; 17(1): 11-13.
26. Garuoliene K. New pharmaceutical policy in Lithuania. Presentation at a PPRI Network Meeting. Riga: PPRI; February 2011.
27. Garuoliene K et al. Pharmaceutical policy and the effects of the economic crisis: Lithuania. Eurohealth 2011; 17(1): 1-4.
28. Rüütel D, Pudersell K. Pharmaceutical policy and the effects of the economic crisis. Estonia. Eurohealth 2011; 17(1): 5-8.
29. Behmane D, Innus J. Pharmaceutical policy and the effects of the economic crisis. Latvia. Eurohealth 2011; 17(1): 8-10.
30. Mossialos E, Oliver A. An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. Int J Health Plann Manage. 2005; 20:291-306.
31. Walley T et al. Supply and regulation of medicines. BMJ 2005; 331:171-2.
32. Kazakov R. Pricing and reimbursement policies in new EU accession countries. J Gene Med. 2007; 4: 249-58.
33. Simoens S. Generic medicine pricing in Europe: current issues and future perspective. J Med Econ. 2008; 11:171-5.
34. Rosian I et al. Benchmarking pharmaceuticals. Market control in nine European countries. Vienna: ÖBIG; 1998.
35. Mullard A. Mediator scandal rocks French medical community. Lanclet 2011; 377:890-892.
36. Buysse, I.M. Impact of the economic recession on the pharmaceutical sector. Utrecht University, WHO CC for Pharmacoepidemiology & Pharmaceutical Policy Analysis, 2010. http://www.pharmaceuticalpolicy.nl/Publications/Reports/Buysse_report%20impact%20recession_2010.pdf (8 August 2011).
37. Sorenson C et al. Ensuring value for money in health care: the role of health technology assessment in the European Union. London, European Observatory for Health Systems and Policies; 2008.
38. Drummond M et al. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur J Health Econ. 2010; 12(3):263-271
39. Leopold C et al. Implementing a successful reference price system - Experiences from other countries [in German]. Soziale Sicherheit 2008; 11:614-23.
40. Godman B et al. Use of generics - A critical cost-containment measure for all healthcare professionals. Pharmaceuticals 2010; 3:2470-94.
41. Godman B et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev. Pharmacoeconomics Outcomes Res. 2010; 10(6):707-22.
42. Godman B et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Frontiers in Pharmacology 2011; 1(141):1-16.
43. Brabant M. Insulin giant pulls medicine from Greece over price cut. In: BBC News. 29 May 2010. http://news.bbc.co.uk/2/hi/world/europe/10189367.stm (8 August 2011).
44. Internal information collected by the Pharma Price Information (PPI) service. Information about PPI available at http://www.goeg.at/en/PPI. (8 August 2011).